Skip to main content
Erschienen in: Abdominal Radiology 2/2018

02.12.2017

Imaging findings of recurrent pancreatic cancer following resection

verfasst von: S. Javadi, N. Karbasian, P. Bhosale, S. de Castro Faria, O. Le, M. H. Katz, E. J. Koay, E. P. Tamm

Erschienen in: Abdominal Radiology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Pancreatic cancer is a challenging malignancy to treat, largely due to aggressive regional involvement, early systemic dissemination, high recurrence rate, and subsequent low patient survival. Generally, 15–20% of newly diagnosed pancreatic cancers are candidates for possible curative resection. Eighty percent of these patients, however, will experience locoregional or distant recurrence in first 2 years. Although there is no strong evidence-based guideline for optimal surveillance after pancreatic cancer resection, careful comparison of surveillance follow-up multi-detector CT (MDCT) studies with a postoperative baseline MDCT examination aids detection of early recurrent pancreatic cancer. In this review article, we describe imaging findings suggestive of recurrent pancreatic cancer and review routine and alternative imaging options.
Literatur
1.
Zurück zum Zitat Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. Cancer J Clin 62:10–29CrossRef Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. Cancer J Clin 62:10–29CrossRef
2.
Zurück zum Zitat Barugola G, Partelli S, Marcucci S, et al. (2009) Resectable pancreatic cancer: who really benefits from resection? Ann Surg Oncol 16:3316–3322CrossRefPubMed Barugola G, Partelli S, Marcucci S, et al. (2009) Resectable pancreatic cancer: who really benefits from resection? Ann Surg Oncol 16:3316–3322CrossRefPubMed
3.
Zurück zum Zitat Kimura K, Amano R, Nakata B, et al. (2014) Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma. World J Surg Oncol 12:360CrossRefPubMedPubMedCentral Kimura K, Amano R, Nakata B, et al. (2014) Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma. World J Surg Oncol 12:360CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Cloyd JM, Katz MH, Prakash L, et al. (2017) Preoperative therapy and pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a 25-year single-institution experience. J Gastroint Surg 21:164–174CrossRef Cloyd JM, Katz MH, Prakash L, et al. (2017) Preoperative therapy and pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a 25-year single-institution experience. J Gastroint Surg 21:164–174CrossRef
5.
Zurück zum Zitat Khorana AA, Mangu PB, Berlin J, et al. (2017) Potentially curable pancreatic cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol 35:2324–2328CrossRefPubMed Khorana AA, Mangu PB, Berlin J, et al. (2017) Potentially curable pancreatic cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol 35:2324–2328CrossRefPubMed
6.
Zurück zum Zitat Khatcheressian JL, Wolff AC, Smith TJ, et al. (2006) American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 24:5091–5097CrossRefPubMed Khatcheressian JL, Wolff AC, Smith TJ, et al. (2006) American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 24:5091–5097CrossRefPubMed
7.
Zurück zum Zitat Desch CE, Benson AB 3rd, Somerfield MR, et al. (2005) Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 23:8512–8519CrossRefPubMed Desch CE, Benson AB 3rd, Somerfield MR, et al. (2005) Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 23:8512–8519CrossRefPubMed
8.
Zurück zum Zitat O’Reilly EM, Lowery MA (2012) Postresection surveillance for pancreatic cancer performance status, imaging, and serum markers. Cancer Journal (Sudbury, Mass) 18:609–613 O’Reilly EM, Lowery MA (2012) Postresection surveillance for pancreatic cancer performance status, imaging, and serum markers. Cancer Journal (Sudbury, Mass) 18:609–613
9.
Zurück zum Zitat NCCN clinical practice gudielines in oncology: pancreatic adenocarcinoma. In 2012; Version 2. NCCN clinical practice gudielines in oncology: pancreatic adenocarcinoma. In 2012; Version 2.
10.
Zurück zum Zitat Cascinu S, Falconi M, Valentini V, Jelic S (2010) Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v55–58CrossRefPubMed Cascinu S, Falconi M, Valentini V, Jelic S (2010) Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v55–58CrossRefPubMed
11.
Zurück zum Zitat Tseng JF, Raut CP, Lee JE, et al. (2004) Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 8:935–949; discussion 949–950 Tseng JF, Raut CP, Lee JE, et al. (2004) Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 8:935–949; discussion 949–950
12.
Zurück zum Zitat Katz MH, Fleming JB, Pisters PW, Lee JE, Evans DB (2008) Anatomy of the superior mesenteric vein with special reference to the surgical management of first-order branch involvement at pancreaticoduodenectomy. Ann Surg 248:1098–1102CrossRefPubMed Katz MH, Fleming JB, Pisters PW, Lee JE, Evans DB (2008) Anatomy of the superior mesenteric vein with special reference to the surgical management of first-order branch involvement at pancreaticoduodenectomy. Ann Surg 248:1098–1102CrossRefPubMed
13.
Zurück zum Zitat Ishigami K, Yoshimitsu K, Irie H, et al. (2008) Significance of perivascular soft tissue around the common hepatic and proximal superior mesenteric arteries arising after pancreaticoduodenectomy: evaluation with serial MDCT studies. Abdom Imaging 33:654–661CrossRefPubMed Ishigami K, Yoshimitsu K, Irie H, et al. (2008) Significance of perivascular soft tissue around the common hepatic and proximal superior mesenteric arteries arising after pancreaticoduodenectomy: evaluation with serial MDCT studies. Abdom Imaging 33:654–661CrossRefPubMed
14.
Zurück zum Zitat Golcher H, Brunner TB, Witzigmann H, et al. (2015) Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlentherapie und Onkologie 191:7–16CrossRefPubMed Golcher H, Brunner TB, Witzigmann H, et al. (2015) Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlentherapie und Onkologie 191:7–16CrossRefPubMed
15.
Zurück zum Zitat Casadei R, Di Marco M, Ricci C, et al. (2015) Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastroint Surg 19:1802–1812CrossRef Casadei R, Di Marco M, Ricci C, et al. (2015) Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastroint Surg 19:1802–1812CrossRef
16.
Zurück zum Zitat Evans DB, Varadhachary GR, Crane CH, et al. (2008) Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26:3496–3502CrossRefPubMed Evans DB, Varadhachary GR, Crane CH, et al. (2008) Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26:3496–3502CrossRefPubMed
17.
Zurück zum Zitat Van den Broeck A, Sergeant G, Ectors N, et al. (2009) Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol 35:600–604CrossRefPubMed Van den Broeck A, Sergeant G, Ectors N, et al. (2009) Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol 35:600–604CrossRefPubMed
18.
Zurück zum Zitat Howard TJ, Krug JE, Yu J, et al. (2006) A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon’s contribution to long-term survival in pancreatic cancer. J Gastrointest Surg 10:1338–1345; discussion 1345–1336 Howard TJ, Krug JE, Yu J, et al. (2006) A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon’s contribution to long-term survival in pancreatic cancer. J Gastrointest Surg 10:1338–1345; discussion 1345–1336
19.
Zurück zum Zitat Ozaki H, Hiraoka T, Mizumoto R, et al. (1999) The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today 29:16–22CrossRefPubMed Ozaki H, Hiraoka T, Mizumoto R, et al. (1999) The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today 29:16–22CrossRefPubMed
20.
Zurück zum Zitat Pawlik TM, Gleisner AL, Cameron JL, et al. (2007) Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 141:610–618CrossRefPubMed Pawlik TM, Gleisner AL, Cameron JL, et al. (2007) Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 141:610–618CrossRefPubMed
21.
Zurück zum Zitat Shimada K, Sakamoto Y, Nara S, Esaki M, Kosuge T, Hiraoka N. (2010) Analysis of 5-year survivors after a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma. World J Surg Shimada K, Sakamoto Y, Nara S, Esaki M, Kosuge T, Hiraoka N. (2010) Analysis of 5-year survivors after a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma. World J Surg
22.
Zurück zum Zitat Winter JM, Cameron JL, Campbell KA, et al. (2006) 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 10:1199–1210; discussion 1210–1191 Winter JM, Cameron JL, Campbell KA, et al. (2006) 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 10:1199–1210; discussion 1210–1191
23.
Zurück zum Zitat Varadhachary GR, Tamm EP, Abbruzzese JL, et al. (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13:1035–1046CrossRefPubMed Varadhachary GR, Tamm EP, Abbruzzese JL, et al. (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13:1035–1046CrossRefPubMed
24.
Zurück zum Zitat Abrams RA, Grochow LB, Chakravarthy A, et al. (1999) Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int J Radiat Oncol Biol Phys 44:1039–1046CrossRefPubMed Abrams RA, Grochow LB, Chakravarthy A, et al. (1999) Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int J Radiat Oncol Biol Phys 44:1039–1046CrossRefPubMed
25.
Zurück zum Zitat Kinsella TJ, Seo Y, Willis J, et al. (2008) The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer. Am J Clin Oncol 31:446–453CrossRefPubMed Kinsella TJ, Seo Y, Willis J, et al. (2008) The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer. Am J Clin Oncol 31:446–453CrossRefPubMed
26.
Zurück zum Zitat Nishio K, Kimura K, Amano R, et al. (2017) Preoperative predictors for early recurrence of resectable pancreatic cancer. World J Surg Oncol 15:16CrossRefPubMedPubMedCentral Nishio K, Kimura K, Amano R, et al. (2017) Preoperative predictors for early recurrence of resectable pancreatic cancer. World J Surg Oncol 15:16CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat La Torre M, Nigri G, Lo Conte A, et al. (2014) Is a preoperative assessment of the early recurrence of pancreatic cancer possible after complete surgical resection? Gut Liver 8:102–108CrossRefPubMed La Torre M, Nigri G, Lo Conte A, et al. (2014) Is a preoperative assessment of the early recurrence of pancreatic cancer possible after complete surgical resection? Gut Liver 8:102–108CrossRefPubMed
28.
Zurück zum Zitat Gutt R, Liauw SL, Weichselbaum RR (2009) Adjuvant radiotherapy for resected pancreatic cancer: a lack of benefit or a lack of adequate trials? Nat Clin Pract Gastroenterol Hepatol 6:38–46CrossRefPubMed Gutt R, Liauw SL, Weichselbaum RR (2009) Adjuvant radiotherapy for resected pancreatic cancer: a lack of benefit or a lack of adequate trials? Nat Clin Pract Gastroenterol Hepatol 6:38–46CrossRefPubMed
29.
Zurück zum Zitat Varadhachary GR, Wolff RA, Crane CH, et al. (2008) Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26:3487–3495CrossRefPubMed Varadhachary GR, Wolff RA, Crane CH, et al. (2008) Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26:3487–3495CrossRefPubMed
30.
Zurück zum Zitat Tzeng CW, Fleming JB, Lee JE, et al. (2012) Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB 14:365–372CrossRefPubMedPubMedCentral Tzeng CW, Fleming JB, Lee JE, et al. (2012) Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB 14:365–372CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Hishinuma S, Ogata Y, Tomikawa M, et al. (2006) Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastroint Surg 10:511–518CrossRef Hishinuma S, Ogata Y, Tomikawa M, et al. (2006) Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastroint Surg 10:511–518CrossRef
32.
Zurück zum Zitat Kayahara M, Nagakawa T, Ueno K, et al. (1993) An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer 72:2118–2123CrossRefPubMed Kayahara M, Nagakawa T, Ueno K, et al. (1993) An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer 72:2118–2123CrossRefPubMed
33.
Zurück zum Zitat Neoptolemos JP, Stocken DD, Friess H, et al. (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210CrossRefPubMed Neoptolemos JP, Stocken DD, Friess H, et al. (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210CrossRefPubMed
34.
Zurück zum Zitat Strobel O, Hartwig W, Hackert T, et al. (2013) Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Ann Surg Oncol 20:964–972CrossRefPubMed Strobel O, Hartwig W, Hackert T, et al. (2013) Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Ann Surg Oncol 20:964–972CrossRefPubMed
35.
Zurück zum Zitat Horvat N, Godfrey EM, Sadler TJ, et al. (2017) Subclinical focal Cholangitis mimicking liver metastasis in asymptomatic patients with history of pancreatic Ductal Adenocarcinoma and Biliary tree intervention. Cancer Imaging 17:21CrossRefPubMedPubMedCentral Horvat N, Godfrey EM, Sadler TJ, et al. (2017) Subclinical focal Cholangitis mimicking liver metastasis in asymptomatic patients with history of pancreatic Ductal Adenocarcinoma and Biliary tree intervention. Cancer Imaging 17:21CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Borad MJ, Saadati H, Lakshmipathy A, et al. (2009) Skeletal metastases in pancreatic cancer: a retrospective study and review of the literature. Yale J Biol Med 82:1–6PubMedPubMedCentral Borad MJ, Saadati H, Lakshmipathy A, et al. (2009) Skeletal metastases in pancreatic cancer: a retrospective study and review of the literature. Yale J Biol Med 82:1–6PubMedPubMedCentral
37.
Zurück zum Zitat Joffe N, Antonioli DA (1978) Osteoblastic bone metastases secondary to adenocarcinoma of the pancreas. Clin Radiol 29:41–46CrossRefPubMed Joffe N, Antonioli DA (1978) Osteoblastic bone metastases secondary to adenocarcinoma of the pancreas. Clin Radiol 29:41–46CrossRefPubMed
38.
Zurück zum Zitat Groot VP, Rezaee N, Wu W, et al. (2017) Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg Groot VP, Rezaee N, Wu W, et al. (2017) Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg
39.
Zurück zum Zitat Kitajima K, Murakami K, Yamasaki E, et al. (2010) Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. Mol Imaging Biol 12:452–459CrossRefPubMed Kitajima K, Murakami K, Yamasaki E, et al. (2010) Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. Mol Imaging Biol 12:452–459CrossRefPubMed
40.
Zurück zum Zitat Ruf J, Lopez Hanninen E, Oettle H, et al. (2005) Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 5:266–272 Ruf J, Lopez Hanninen E, Oettle H, et al. (2005) Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 5:266–272
41.
Zurück zum Zitat Sperti C, Pasquali C, Bissoli S, et al. (2010) Tumor relapse after pancreatic cancer resection is detected earlier by 18-FDG PET than by CT. J Gastroint Surg 14:131–140CrossRef Sperti C, Pasquali C, Bissoli S, et al. (2010) Tumor relapse after pancreatic cancer resection is detected earlier by 18-FDG PET than by CT. J Gastroint Surg 14:131–140CrossRef
42.
Zurück zum Zitat Izuishi K, Yamamoto Y, Sano T, et al. (2010) Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer. J Gastrointest Surg 14:1151–1158CrossRefPubMed Izuishi K, Yamamoto Y, Sano T, et al. (2010) Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer. J Gastrointest Surg 14:1151–1158CrossRefPubMed
43.
Zurück zum Zitat Kitajima K, Murakami K, Yamasaki E, et al. (2009) Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. Mol Imaging Biol Kitajima K, Murakami K, Yamasaki E, et al. (2009) Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. Mol Imaging Biol
44.
Zurück zum Zitat Cameron K, Golan S, Simpson W, et al. (2011) Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT). Abdom Imaging 36:463–471CrossRefPubMed Cameron K, Golan S, Simpson W, et al. (2011) Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT). Abdom Imaging 36:463–471CrossRefPubMed
45.
Zurück zum Zitat Higashi T, Saga T, Nakamoto Y, et al. (2003) Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) –usefulness and limitations in “clinical reality”. Ann Nuclear Med 17:261–279CrossRef Higashi T, Saga T, Nakamoto Y, et al. (2003) Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) –usefulness and limitations in “clinical reality”. Ann Nuclear Med 17:261–279CrossRef
46.
Zurück zum Zitat Belyaev O, Munding J, Tannapfel A, Uhl W (2015) False-positive PET/CT after cyanoacrylate sealing of a pancreaticojejunostomy. J Gastrointest Surg 19:984–985CrossRefPubMed Belyaev O, Munding J, Tannapfel A, Uhl W (2015) False-positive PET/CT after cyanoacrylate sealing of a pancreaticojejunostomy. J Gastrointest Surg 19:984–985CrossRefPubMed
47.
Zurück zum Zitat Diederichs CG, Staib L, Vogel J, et al. (2000) Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 20:109–116CrossRefPubMed Diederichs CG, Staib L, Vogel J, et al. (2000) Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 20:109–116CrossRefPubMed
48.
Zurück zum Zitat Jung W, Jang JY, Kang MJ, et al. (2016) The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patients. HPB 18:57–64CrossRefPubMed Jung W, Jang JY, Kang MJ, et al. (2016) The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patients. HPB 18:57–64CrossRefPubMed
49.
Zurück zum Zitat Fritz F, Skornitzke S, Hackert T, et al. (2016) Dual-energy perfusion-CT in recurrent pancreatic cancer—preliminary results. RoFo 188:559–565CrossRefPubMed Fritz F, Skornitzke S, Hackert T, et al. (2016) Dual-energy perfusion-CT in recurrent pancreatic cancer—preliminary results. RoFo 188:559–565CrossRefPubMed
Metadaten
Titel
Imaging findings of recurrent pancreatic cancer following resection
verfasst von
S. Javadi
N. Karbasian
P. Bhosale
S. de Castro Faria
O. Le
M. H. Katz
E. J. Koay
E. P. Tamm
Publikationsdatum
02.12.2017
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 2/2018
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-017-1397-8

Weitere Artikel der Ausgabe 2/2018

Abdominal Radiology 2/2018 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.